Expanded Access for ATB200/AT2221 for the Treatment of IOPD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an expanded access program (EAP) for eligible participants designed to provide access to ATB200/AT2221.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221

NCT02675465

Pompe Disease

COMPLETED PHASE1/PHASE2

Drug-drug Interaction Study

NCT01380743

Pompe Disease

COMPLETED PHASE2

Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa

NCT04910776

Glycogen Storage Disease Type II

ACTIVE_NOT_RECRUITING PHASE3

Tideglusib: Expanded Access Use in Congenital Myotonic Dystrophy

NCT07119775

Congenital Myotonic Dystrophy

AVAILABLE

China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD

NCT06666413

Glycogen Storage Disease Type II Pompe's Disease

RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This program is being offered on a patient by patient basis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pompe Disease Infantile-Onset

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ATB200

Participants received ATB200 co-administered with AT2221 capsule (Miglustat)

Intervention Type BIOLOGICAL

AT2221

Participants received ATB200 co-administered with AT2221 capsule (Miglustat)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient is male or female and 0 to \< 18 years old.
2. Patient has a diagnosis of Pompe disease, based on documentation of GAA genotyping demonstrating variants associated with IOPD.
3. Patient does not currently qualify for or is unable to enroll (eg, due to location, etc) in any commercial drug-sponsored ongoing clinical trial.
4. Patient is currently being treated with an approved ERT and is declining (eg, worsening in motor function, respiratory function/parameters, cardiac function, etc) based on treating physician's clinical judgement.
5. The patient's legal guardian or representative has given informed consent (and assent when age appropriate for regional requirements) to treatment prior to administering ATB200/AT2221 in a manner consistent with all national requirements.
6. If of reproductive potential and sexually active, female subjects agree to use a highly effective method of contraception throughout the duration of the treatment and for up to 90 days after their last dose of ATB200/AT2221.

Exclusion Criteria

1. Patient has a hypersensitivity to any of the excipients in ATB200, alglucosidase alfa, or AT2221
2. Patient has a medical or any other extenuating condition or circumstance that may, in the opinion of the investigator and/or Amicus, pose an undue safety risk to the patient.
3. Concomitant use of miglitol (eg, Glyset), non-AT2221 form of miglustat (eg, Zavesca), acarbose (eg, Precose or Glucobay), voglibose (eg, Volix, Vocarb,or Volibo)

Minimum Eligible Age

0 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No